The volume of production vaccines against coronavirus will soon be more than sufficient to ensure the vaccination of all, pharmaceutical companies assured on Tuesday, and while inequality between rich and poor countries in vaccinations remains high.
As stated in a press conference Thomas Quinney, Director-General of the International Federation of Pharmaceutical Industries (IFPMA), the 7.5 billion doses of vaccine which will be prepared will be exceeded in September.
Today, according to data analysis company Airfinity, 1.5 billion doses vaccines are prepared every month, broadcasts by ΑΠΕ ΜΠΕ.
By the end of 2021, global vaccine production for Covid is expected to reach 12 billion doses.
And even if Western countries launch campaigns booster doses vaccination for people over 12 years of age, at least 1.2 billion doses will remain available for redistribution, according to Airfinity.
“This means that governments always maintain installment reserves in the event of a shortage not “They need to do it now.”
However, large-scale vaccination campaigns are being carried out in Western countries, and in some of them more than 70% of the population has received both the required doses, only the 6% of adults Of Africans has been fully immunized against Covid-19.
According to a count of the French Agency in Africa today broke their barrier 200,000 deaths related to the pandemic since its inception.
Under these circumstances, the industry emphasizes that they are calling for collaborations with governments to help development of vaccination campaigns.
Overall, by mid-2022, total vaccine production is expected to reach 24 billion doses, according to IFPMA, which estimates that production can exceed global demand.
“Then we will have the same problem that exists in high-income countries, with people refusing to be vaccinated,” he told a news conference. Albert Burla, CEO of American Pharmaceutical Company Pfizer, waiting 3 billion doses to be produced this year.
For Bourlas, vaccine availability problems were initially caused by lack of raw materials. “Cost is not the problem,” he said, noting that Pfizer has implemented a different pricing system based on countries’ incomes.
Regarding her issue removal of patents of vaccines, this would not solve anything, say the manufacturers.
“At the moment, the aim is to optimize existing vaccine production capabilities by people who know how to produce them “, he judged Paul Stoffels, Scientific Director of Johnson & Johnson.
“If it took us 18 months to increase our capacity in existing factories (…), that would take much more time for other companies. That does not help, “he said.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
